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Tetanus and botulinum neurotoxins cause paralysis by cleaving SNARE proteins within the cytosol
of nerve terminals. They are endocytosed inside acidic vesicles and the pH gradient across the mem-
brane drives the translocation of their metalloprotease L domain in the cytosol. This domain is
linked to the rest of the molecule by a single interchain disulﬁde bridge that has to be reduced
on the cytosolic side of the membrane to free its enzymatic activity. By using speciﬁc inhibitors of
the various cytosolic protein disulﬁdes reducing systems, we show here that the NADPH-thioredoxin
reductase-thioredoxin redox system is the main responsible for this disulﬁde reduction. In addition,
we indicate auranoﬁn, as a possible basis for the design of novel inhibitors of these neurotoxins.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bacteria of the genus Clostridium produce one tetanus neuro-
toxin (TeNT) which causes the spastic paralysis of tetanus and se-
ven different botulinum neurotoxins (BoNT/A, /B, /C, /D, /E, /F, and /
G) which cause the ﬂaccid paralysis of botulism [1]. They differ for
antigenic properties and for their intracellular targets [2,3]. They
have a similar four-domains structure [4–7] which makes them
capable of entering, via a four step mechanism, the cytosol of nerve
terminals [7–9]. Only the N-terminal domain of 50 kDa, termed L
chain, reaches the cytosol where it cleaves the three SNARE pro-
teins which form the core of the neuroexocytosis apparatus thus
blocking neurotransmitter release causing paralysis [10,11]. Teta-
nus has been a major killer in the past, but nowadays it is pre-
vented by a very effective vaccine except for those countries not
provided with an operative system of preventive medicine [12].
Botulinum neurotoxins are so toxic to humans (MLD50 is in the
range of 0.2–1 ng/kg) as to be considered for potential use in biot-errorism [13], but, at the same time, they are currently used as
therapeutics to treat a number of human syndromes characterized
by hyperfunction of peripheral nerve terminals [14–16]. Human
botulism is rare, and it follows the ingestion of BoNT contaminated
food or of spores of neurotoxigenic Clostridia, contamination of
wounds or excessive dosage during cosmetic treatments [1,17].
The duration of human botulism depends on the amount and type
of BoNT, with BoNT/A and /C having the longest duration and
BoNT/E the shortest [1,18,19]. This situation calls for the develop-
ment of novel drugs that can counteract TeNT and BoNT action by
affecting any of the four steps of the mechanism of intoxication: (a)
binding; (b) endocytosis; (c) membrane translocation and (d)
metalloprotease cleavage of SNAREs. Before their binding to the
presynaptic membrane of neurons, the toxins are best neutralized
by speciﬁc anti-toxin antibodies [20,21] which prevent the ﬁrst
step of the entry of TeNT and BoNT into their target neurons.
Currently, several groups are attempting to block any of the three
subsequent steps [22–30].
The present knowledge on the mode of membrane translocation
of these neurotoxins is summarized in a model which envisages
the insertion of the HN domain into the membrane of the acidic
toxin-containing vesicle to form a ion channel which acts as a
chaperone assisting the unfolding and translocation of the L chain,
which remains linked to the HN domain via a single interchain
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pH of the cytosol and detaches following reduction of the inter-
chain SS bond by an unknown reducing agent of the cytosol [32].
An intact SS bond is essential for neurotoxicity [33,34] and for
translocation of the L chain and it must be reduced on the cytosolic
side [32].
There are several disulphide bond reducing systems in the cyto-
sol of cells [35,36] and, here, we have used a pharmacological ap-
proach to identify which of them is involved in the reduction of the
interchain SS bond of TeNT and BoNTs. At the same time, this study
has identiﬁed a molecule, which may lead to novel drugs effective
for the treatment of tetanus and botulism patients.
2. Materials and methods
2.1. Reagents
Auranoﬁn, (1-thio-b-D-glucopyranosatotriethylphosphine gold-
2,3,4,6-tetraacetate) BSO (buthionine-sulfoximine), ATO (arsenic
trioxide), KAuCL4 (potassium tetrachloroaurate(III) hydrate), cDDP
(cisplatin), cytosine arabinoside, DNAse I, poly-L-lysine, were pur-
chased from Sigma Aldrich. Anti-VAMP2 Mab, anti-Syntaxin Mab
were from Synaptic System. TeNT, BoNT/B, and /C were puriﬁed
as previously described [37,38] whilst BoNT/D was produced in
Escherichia coli via recombinant methods as described [39].
2.2. Cell cultures
Primary cultures of rat cerebellar granule neurons (CGNs) were
prepared from 6- to 8-days-old rats [40]. Brieﬂy, rat cerebella were
ﬁrstly mechanically disrupted and then trypsinated in the presence
of DNase I. Cells were collected and plated into 24 well plates,
coated with poly-L-lysine (50 lg/ml), at cell density of 3  105 cells
per well. Cultures were maintained at 37 C, 5% CO2, 95% humidity
in BME supplemented with 10% fetal bovine serum, 25 mM KCl,
2 mM glutamine an 50 lg/ml gentamycin. To arrest growth of
non-neuronal cells, cytosine arabinoside (10 lM) was added to
the medium 18–24 h after plating.
2.3. Assay of inhibitors of the intoxication of CGNs with tetanus and
botulinum neurotoxins
CGNs were used at 6–8 div. Cells were pre-incubated with AF or
BSO or ATO or cisplatin or KAuCl4 at increasing concentrations in
BME 10% FBS, 25 mM KCl and left for 6 h at 37 C and 5% CO2. Then
the indicated toxin was added and left for 15 min at 37 C. There-
after, the cells were washed with BME in order to remove the toxin
and the normal culture medium was restored with the indicated
concentration of inhibitor for 12 h at 37 C. The translocation of
the L chains of the various neurotoxins was evaluated following
their speciﬁc proteolytic activity by immunoblotting with anti-
SNAREs antibodies.
2.4. Immunoblotting
Cells were lysed with 100 mM Tris–HCl, 1% SDS, pH 6.8, contain-
ing protease inhibitors (complete Mini EDTA-free, Roche). Protein
concentration was determined with the BCA test (Pierce BCA pro-
tein assay, Thermo Scientiﬁc), and equal amounts were loaded onto
a 4–12% NuPage gel (Invitrogen) and separated by electrophoresis
in 1MES buffer (Invitrogen). Proteins were then transferred onto
Protran nitrocellulose membranes (Whatman) and then saturated
for 1 h in PBS-T (PBS 0.1% Tween 20) containing 5% non-fat milk.
Incubation with primary antibodies (speciﬁc for VAMP2 and Syn-
taxin 1A) was performed overnight at 4 C. The membranes werewashed three times with PBS-T and incubated with secondary anti-
bodies HRP-conjugated. Finally membranes were washed several
times with PBS-T and visualization was carried out using the Lumi-
nata Crescendo (Merck Millipore). The amount of cleaved VAMP
(TeNT, BoNT/B and /D) was determined as a ratio with respect to
Syntaxin 1A, whilst the opposite was done in the case of BoNT/C.
2.5. In vitro proteolytic activity
TeNT and BoNT/D (2 lg) were treated with reducing buffer
(150 mM NaCl, 10 mM NaH2PO4, 15 mM DTT pH 7.4) for 30 min
at 37 C. The activated toxins were split into different tubes and
in half of them AF was added (1 lM ﬁnal concentration). Five
micrograms of recombinant GST-VAMP2 was added in each tube
and the reaction was left for 2 h at 37 C. SNARE cleavage was as-
sessed by Comassie staining in SDS–PAGE.
2.6. Viability test
CGNs were seeded in a 96 wells plate at a cell density of 105
cells per well. After 6 div, different concentration of AF, ranging
from 0 to 10 lM, were added and left for 24 h. Neurons were then
washed and MTS assay (Promega) performed according to supplier
indication. Absorbance was recorded at 490 nm using a Spectra
Count™ plate reader (Canberra Industries, Meridien, USA) and cell
viability has been reported as percentage vs. non-treated neurons.
2.7. BoNT/D LD50 assay
For in vivo experiments Swiss-Webster adult male CD1 mice
weighing 25–30 g were used. Mice were housed under controlled
light/dark conditions and food and water was provided ad libitum.
All experiments were performed in accordance with the Italian
guidelines, law n. 116/1992 and were approved by the Animal Eth-
ical Committee of our University. AF was dissolved in a stock solu-
tion with ethanol. Mice were i.p. injected (injection volume 250 ll)
with 12 mg of AF per kg of body weight or with the vehicle (0.9%
NaCl). Animals were incubated for 6 h before the injection of the
indicated dose of BoNT/D diluted in 0.9% NaCl (injection volume
250 ll). The animals were monitored every 3 h for 96 h, after
which the experiment was considered ended.
2.8. Estimation of thioredoxins reductase activity
Thioredoxin reductase activity was assayed as previously de-
scribed [41]. Brieﬂy, 0.1 mg of cell extract was tested at room tem-
perature in 0.2 M Na,K-phosphate buffer (pH 7.4), supplemented
with 2 mM EDTA and 0.4 mM NADPH. Reactions were started add-
ing 2 mM DTNB and its reduction was followed spectrophotomet-
rically at 412 nm. Values after 1 min after start had been reported.
3. Results
The major protein disulﬁde reducing systems of the cell cytosol,
in addition to the glutathione pool, are the NADPH-thioredoxin
reductase-thioredoxin (Trx) system [35] and the glutathione-glut-
aredoxin system [36]. They are implicated in controlling a variety
of cell functions altered in a number of human diseases [42].
Accordingly a large number of drugs have been developed to be
evaluated as candidate drugs for clinical use [43,44]. We have ta-
ken here a pharmacological approach and used a set of inhibitors
of these cell disulphide reducing system to identify which of them
is implicated in the reduction of the interchain disulphide bond of
clostridial neurotoxins, a reduction that takes place in the cytosol
[32–34].
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well characterized for the depletion of the cytosolic pool of gluta-
thione [43,44]. Under conditions in which residual GSH of cerebel-
lar granular neurons was lowered by these drugs below 20% of the
normal content, no effect on the VAMP2 cleavage induced by
BoNT/D and TeNT was observed (Fig. S1 A and B), indicating that
neither GSH nor the glutathione-glutaredoxin system play a rele-
vant role in the process. This negative result left open the possibil-
ity that the Trx system might be implicated.
Several inhibitors of the Trx system are available, including cur-
cumin and other ﬂavonoids, cisplatin, KAuCl4, but the most speciﬁc
one is auranoﬁn (AF) [45]. An attractive feature of AF is that it is
currently used in the treatment of human rheumatoid arthritis
[46] in addition to being considered for the treatment of different
forms of cancers and HIV infection [45,47].
Fig. 1B shows that AF protects cerebellar granular neurons from
the action of different doses of tetanus neurotoxin (TeNT) and that
about 1 lM AF confers a full protection against TeNT intoxication
(Fig. 1A), measured as cleavage of VAMP-2, while it does not affect
cell vitality (Fig. S2).
The inhibitory effect of AF is not limited to TeNT as it protects
CGN from the cleavage of VAMP-2 induced by BoNT/B (panel A
of Fig. 2) and the cleavage of syntaxin 1A induced by BoNT/C
(Fig. 2B). It is noteworthy that AF protects the intoxication of
CGN from different neurotoxins in the same range of concentra-
tions. This is consistent with an action of AF on the same step of
the intoxication process. Auranoﬁn is reported to be very speciﬁc
for Trx [41,48,49], however we tested its ability to inhibit the Trx
of CGN. Fig. S3 shows that the same holds true for the neurons used
here. The different range of concentration values found for the
inhibition of the activity of the neurotoxins and for the Trx inhibi-
tion could be attributed to the different permeability of the plasma
membrane of AF in different cell lines (or to the different activity of
Trx in different cell types) [41].
In addition to syntaxin, BoNT/C cleaves SNAP-25 [50]. However,
we could not quantify the inhibitory activity of AF on the action of
BoNT/C on its second substrate because AF interferes with the
immunoblotting assay of SNAP-25 cleavage used here. As AF inter-Fig. 1. TeNT cleavage of VAMP is inhibited by auranoﬁn in cerebellar granular neurons. T
1 lM of auranoﬁn (B, empty bars) at 37 C, washed with culture medium and incubate
culture medium, washed and incubated for 12 h at 37 C in the presence of the report
without auranoﬁn. Cells were lysed and the SNARE proteins were estimated by immuno
densitometry and its percentage ratio with syntaxin 1A plotted, taking the value in
experiments performed in triplicates. The lower panel shows a representative immunobacts with selenium and sulfur containing compounds, it might as
well interact with the cysteine quartet of SNAP-25 after cell solu-
bilization. In vivo, this does not occur as AF is not cytotoxic to neu-
rons, and no AF neurological side effects in humans have been
reported. This difference is likely to be due to the fact that the
SNAP-25 cysteine quartet is inserted in the membrane and is
therefore protected from the interaction with AF. However, this ef-
fect of AF prevented us to test its activity on BoNT/A and BoNT/E.
We attempted to use two other Trx inhibitors that may overcome
this problem: cisplatin and KAuCl4. However, they were found to
be very toxic to CGN in culture at concentrations close to their re-
ported IC50 (not shown) [48].
In terms of toxicity in mice, the most powerful clostridial neu-
rotoxin is BoNT/D (this preparation gave a LD50 value <0.4 nano-
gram/kg). Fig. 3 shows that AF also protects CGN from the
cleavage of VAMP-2 induced by this neurotoxin type and again in
the same range of concentrations.
The inhibitory activity of AF on the intoxication of neurons by
TeNT and BoNT/B, /C and /D is not due to an effect on the fourth
step of the process, i.e. their metalloprotease activity as control
experiments performed in vitro with toxins and substrates alone
did not reveal in any case an inhibition by AF (not shown).
These results prompted us to test the possible protective activ-
ity of AF in vivo in mice injected with BoNT/D, chosen because it is
the most powerful clostridial neurotoxin in mice. However, AF
used at the dose of 12 mg/kg, corresponding to about 175 lM con-
sidering the total body ﬂuids as 10% of the mouse weight, did not
protect mice from the ﬂaccid paralysis induced by BoNT/D (Fig. 4).
This dose was recently used to show that AF inhibits the activation
of the Nlrp1b inﬂammasome [51].
4. Discussion
The main ﬁnding reported here is that auranoﬁn (AF), a speciﬁc
active site inhibitor of thioredoxin reductase, a member of one of
the major cell protein disulﬁde reducing systems, inhibits the
intracellular activity of TeNT and of BoNT/B, /C and /D. At the same
time, AF does not inhibit the metalloproteolytic activity of the Lhe neurons were pre-incubated for 6 h with the indicated concentrations (A) or with
d with 1 nM (A) or the indicated concentrations of TeNT (B) at 37 C for 15 min in
ed inhibitor concentration. In panel B, black bars represent the samples incubated
blotting with speciﬁc antibodies (lower panel); Residual VAMP2 was quantiﬁed by
non-treated cells (grey bar) as 100%. S.D. values derive from three independent
lotting.
Fig. 2. BoNT/B and C cleavage of VAMP in cerebellar granular neurons is inhibited by auranoﬁn. The neurons were pre-incubated for 6 h with the indicated concentrations of
auranoﬁn at 37 C, washed with BME and incubated with 10 nM BoNT/B (A) or 1 nM BoNT/C (B) at 37 C for 15 min in culture medium, washed and incubated for 12 h at 37 C
in the presence of the reported inhibitor concentration. Cells were lysed and the SNARE proteins were estimated by immunoblotting with speciﬁc antibodies; Residual VAMP2
(A) or residual syntaxin 1A was quantiﬁed by densitometric analysis and its percentage ratio with the respective non-substrate SNARE plotted, taking the value in non-treated
cells (grey bar) as 100%. S.D. values derive from three independent experiments performed in triplicates.
Fig. 3. Auranoﬁn inhibits the VAMP cleavage by BoNT/D in cerebellar granular neurons. The neurons were pre-incubated for 6 h with the indicated concentrations (A) or with
1 lM auranoﬁn (B, empty bars) at 37 C, washed with medium and incubated for 15 min with 0.1 nM (A) or the indicated concentration (B) of BoNT/D at 37 C in culture
medium, washed again and incubated for 12 h at 37 C in the presence of the reported inhibitor concentration. (B) black bars represent the samples incubated without
auranoﬁn. Cells were lysed and the SNARE proteins were estimated by immunoblotting with speciﬁc antibodies; residual VAMP was quantiﬁed as in Fig. 1. S.D. values derive
from three independent experiments performed in triplicates.
Fig. 4. Effect of auranoﬁn on the BoNT/D MLD50 assay. Adult male CD1 mice were
i.p. injected with 12 mg/kg of AF or with the vehicle 6 h before the i.p. injection of
the indicated dose of BoNT/D. The animals were monitored every 3 h for 96 h. S.D.
values derive from three different experiments performed with groups of three
animals each.
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thioredoxin system very efﬁciently reduces in vitro the single
interchain disulﬁde bond of TeNT [33] and of BoNTs (our unpub-
lished results). The reduction of this SS bond in the cytosol is
essential to free the SNARE cleaving activity of the L chain
[31,32]. Taken together, these ﬁndings provide a strong indication
that the thioredoxin system plays a major role, if not a unique one,
in releasing the L chain of TeNT and BoNTs after their translocation
across the membrane of the endocytic vesicle assisted by their
respective HN domains.
An attractive feature of thioredoxins is that they share struc-
tural similarities with group-I and group-II chaperonins [52,53]
and indeed thioredoxins promote the folding of proteins in re-
dox-independent reactions [53–55]. Thus, it is tempting to specu-
late that the thioredoxin system not only detaches the L chain from
the HN domain by severing the remaining disulﬁde link, but also
acts before by assisting the refolding of the L chain as it emerges
from HN transmembrane channel.
The disappointing lack of protective activity of AF on the in vivo
intoxication of mice with BoNT/D can be explained by the fact that
AF does not cross the blood–brain barrier and it may as well be not
capable of reaching the cytosol of the motor axon terminals
154 M. Pirazzini et al. / FEBS Letters 587 (2013) 150–155protected by the terminal Schwann cells on one side and the mus-
cle ﬁber on the other side. However, the present data indicate that
it is possible to use auranoﬁn as a lead to design auranoﬁn-based
novel inhibitor of the clostridial neurotoxins capable of acting
in vivo.
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